Ozempic(R)Superior in Lowering Blood Sugar and Weight Vs Place...
BAGSVÆRD, Denmark, March 5, 2019 /PRNewswire-AsiaNet/ -- Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic(R) (semaglutide) 1.0 mg when add...
Authors: LATEST ASIANET NEWS RELEASES